Trial Profile
A Phase III, Randomized, Double-blind, Controlled Multicenter Study of Intravenous PI3K Inhibitor Copanlisib in Combination With Standard Immunochemotherapy Versus Standard Immunochemotherapy in Patients With Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 25 Apr 2024
Price :
$35
*
At a glance
- Drugs Copanlisib (Primary) ; Bendamustine; Cyclophosphamide; Doxorubicin; Prednisolone; Prednisone; Rituximab; Vincristine
- Indications B-cell lymphoma; Chronic lymphocytic leukaemia; Follicular lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma; Waldenstrom's macroglobulinaemia
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms CHRONOS-4
- Sponsors Bayer
- 11 Jan 2024 This trial has been discontinued in Ireland, according to European Clinical Trials Database record
- 19 Dec 2023 This trial has been discontinued in Germany, according to European Clinical Trials Database record.
- 06 Dec 2023 This trial has been completed in Czechia (Date of the global end of the trial: 10-Nov-2023), according to the European Clinical Trials Database record.